COVID-19 vaccine effectiveness

If you want to see all comparisons, please click here

Novavax - NVX-CoV2373 vs Placebo

Novavax

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots

Evidence profile

Summary of findings


Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04368988
Novavax, Inc
Formica N, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

NVX-CoV2373 5mcg D0/21

NVX-CoV2373 5mcg D0

25mcg NVX-CoV2373 D0/D21

25mcg NVX-CoV2373 D0

Placebo D0/D21

RCT
Phase 2
Healthy adults (stable comorbidities and confirmed COVID-19 with mild symptoms permitted) aged 18-84 years at 17 centers in Australia and USA N=1288
Some concerns
Details

Full description

NCT04583995; EudraCT 2020-004123-16
Novavax
Heath P, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. N=15187
Some concerns
Details

Full description

NCT04368988
Novavax
Keech C, N Engl J Med, 2020

Full text
Commentary
Protein subunit

25mcg NVX-D0/21

5mcg NVX/M1-D0/21

25mcg NVX/M1-D0/21

25mcg NVX/M1+Placebo-D0/2

Placebo

RCT
Phase 1
Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

NCT04533399; PACTR202009726132275
Novavax
Shinde V, N Engl J Med, 2021

Full text
Commentary
Protein subunit

5mcg NVX-CoV2373

Placebo

RCT
Phase 2a/b
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4406
Some concerns
Details

Full description

For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.